5 Key Takeaways

• 1

  As SOTIO Biotech’s chief scientific officer, Amy Jensen-Smith oversees preclinical antibody-drug conjugate programs for solid tumors, from target and technology discovery to clinical readiness.

• 2

  Jensen-Smith said her move from bench science to leadership let her consider broader implications of discoveries while continuing to do science and build teams.

• 3

  For new targets, SOTIO identifies the program’s most critical uncertainty and tests it early to determine whether the idea is worth pursuing.

• 4

  Jensen-Smith described biotech as offering a balance of resources, technology, focus, and freedom for innovative research, based on her experience.

• 5

  She advises scientific leaders to hire people with different backgrounds and work styles, make failure acceptable, and listen to team members’ ideas.